Vertex Pharmaceuticals Incorporated (VRTX) Holdings Lifted by Jag Capital Management LLC
Jag Capital Management LLC raised its holdings in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.0% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 53,003 shares of the pharmaceutical company’s stock after purchasing an additional 4,397 shares during the period. Vertex Pharmaceuticals accounts for about 1.6% of Jag Capital Management LLC’s holdings, making the stock its 29th largest holding. Jag Capital Management LLC’s holdings in Vertex Pharmaceuticals were worth $9,750,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also added to or reduced their stakes in VRTX. Oregon Public Employees Retirement Fund raised its position in Vertex Pharmaceuticals by 16,530.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 4,610,881 shares of the pharmaceutical company’s stock valued at $28,000 after purchasing an additional 4,583,156 shares during the last quarter. FMR LLC raised its position in shares of Vertex Pharmaceuticals by 13.3% in the 4th quarter. FMR LLC now owns 20,483,109 shares of the pharmaceutical company’s stock worth $3,394,256,000 after acquiring an additional 2,411,631 shares in the last quarter. Norges Bank bought a new position in shares of Vertex Pharmaceuticals in the 4th quarter worth approximately $380,584,000. Jennison Associates LLC raised its position in shares of Vertex Pharmaceuticals by 11.9% in the 4th quarter. Jennison Associates LLC now owns 6,941,621 shares of the pharmaceutical company’s stock worth $1,150,296,000 after acquiring an additional 739,128 shares in the last quarter. Finally, AQR Capital Management LLC raised its position in shares of Vertex Pharmaceuticals by 54.0% in the 3rd quarter. AQR Capital Management LLC now owns 1,281,344 shares of the pharmaceutical company’s stock worth $246,966,000 after acquiring an additional 449,549 shares in the last quarter. 95.37% of the stock is owned by institutional investors and hedge funds.
VRTX stock traded down $0.29 on Monday, reaching $182.49. 787,605 shares of the company traded hands, compared to its average volume of 1,438,299. Vertex Pharmaceuticals Incorporated has a one year low of $144.07 and a one year high of $195.81. The firm has a market cap of $46.73 billion, a PE ratio of 64.48, a price-to-earnings-growth ratio of 2.71 and a beta of 1.64.
In other Vertex Pharmaceuticals news, SVP Paul M. Silva sold 4,215 shares of the stock in a transaction on Monday, February 11th. The stock was sold at an average price of $180.16, for a total transaction of $759,374.40. Following the sale, the senior vice president now directly owns 23,386 shares in the company, valued at approximately $4,213,221.76. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, SVP Paul M. Silva sold 3,007 shares of the stock in a transaction on Thursday, January 17th. The shares were sold at an average price of $190.62, for a total value of $573,194.34. Following the sale, the senior vice president now owns 17,376 shares in the company, valued at $3,312,213.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 208,624 shares of company stock worth $38,187,166. Company insiders own 0.75% of the company’s stock.
Several brokerages have recently issued reports on VRTX. Evercore ISI began coverage on Vertex Pharmaceuticals in a research report on Thursday. They issued an “in-line” rating and a $183.00 target price for the company. William Blair raised Vertex Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $183.85 target price for the company in a research report on Tuesday, March 26th. BidaskClub lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Svb Leerink reissued a “market perform” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, March 19th. Finally, Leerink Swann lowered Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating and set a $185.40 target price for the company. in a research report on Tuesday, March 19th. They noted that the move was a valuation call. One analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $203.31.
TRADEMARK VIOLATION WARNING: This story was reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://theolympiareport.com/2019/04/15/vertex-pharmaceuticals-incorporated-vrtx-holdings-lifted-by-jag-capital-management-llc.html.
Vertex Pharmaceuticals Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
See Also: Why do corrections happen?
Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX).
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.